Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis

Journal of Ophthalmic Inflammation and Infection

Table 2 The National Eye Institute 39-Question Visual Function Questionnaire composite and subscale scores divided by treatment group

	Group 1					Group 2
	Median			P value		Median			P value
VFQ-25 Subscales	BL ( n = 13)	M6 ( n = 13)	M12 ( n = 12)	BL-M6	BL-M12	BL ( n = 13)	M6 ( n = 13)	M12 ( n = 11)	BL-M6	BL-M12
General health	73.08	73.08	71.43	1.00	0.80	66.21	70.33	71.75	0.47	0.30
General vision	59.49	70.77	72.78	0.03	0.04	65.13	70.00	70.61	0.18	0.70
Ocular pain	78.85	79.81	88.54	0.79	0.01	67.31	84.62	84.09	0.01	0.01
Near activities	66.35	67.69	76.18	0.73	0.03	73.59	74.74	73.64	0.78	0.56
Distance activities	73.33	79.17	83.96	0.15	0.04	74.36	80.29	78.41	0.12	0.23
Vision-specific social functioning	85.26	89.10	95.49	0.44	0.03	89.74	93.59	92.42	0.31	0.28
Vision-specific mental health	59.68	68.08	78.33	0.07	0.01	59.23	70.77	74.09	0.02	0.06
Vision-specific role difficulties	71.63	75.48	85.42	0.42	0.04	69.71	76.92	80.11	0.07	0.22
Vision-specific dependency	80.29	87.02	92.71	0.16	0.07	85.58	88.94	92.61	0.38	0.26
Driving^a	79.63	81.48	80.21	0.56	0.52	64.58	72.22	70.00	0.08	0.54
Color vision	88.46	94.23	95.83	0.39	0.10	92.31	96.15	93.18	0.44	1.00
Peripheral vision	78.85	81.73	83.33	0.69	0.19	78.85	83.65	75.00	0.41	0.34
Composite score for VFQ-39 (VFQ-25 + additional items)	73.87	78.64	84.87	0.06	0.01	74.67	81.17	80.49	0.03	0.10

Italicized values indicate statistical significance.
^aDriving (group 1): n = 9 for BL-M6 and n = 8 for BL-M12 comparison. Driving (group 2): n = 12 for BL-M6 and n = 10 for BL-M12 comparison.
BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire.